Novartis International AG http://www.novartis.com Novartis QVA149 Phase III COPD studies meet primary endpoints 2012-04-02T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2012/1599186.shtml Novartis delivers strong underlying financial performance in 2011, expects 2012 sales to be in line with 2011 2012-01-25T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2012/1579903.shtml Novartis achieves strong third quarter financial performance and pipeline progress 2011-10-25T08:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1557500.shtml New Novartis data show potential of respiratory portfolio to help COPD patients maintain active and productive lives 2011-09-27T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1549983.shtml Novartis study shows QTI571 significantly improved walking distance in patients with life-threatening pulmonary arterial hypertension 2011-09-25T13:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1549437.shtml Novartis delivers strong financial results and four major approvals in second quarter of 2011 2011-07-19T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1531819.shtml Novartis receives FDA approval for Arcapta(TM) Neohaler(TM), a novel once-daily bronchodilator for chronic obstructive pulmonary disease 2011-07-01T22:38:08 CET http://www.novartis.com/newsroom/media-releases/en/2011/1528013.shtml Novartis Phase III study shows once-daily NVA237 is superior to placebo and similar to tiotropium in improving lung function in COPD 2011-06-30T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1527049.shtml Novartis studies show Onbrez® Breezhaler® plus tiotropium is more effective than tiotropium alone in treatment of COPD 2011-05-15T18:45:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1515988.shtml Novartis makes strong start for the year 2011-04-19T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1507510.shtml FDA advisory committee recommends US approval of Novartis once-daily bronchodilator QAB149 for COPD 2011-03-09T01:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1495541.shtml Innovation drives Novartis to double-digit growth for 2010 2011-01-27T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1482782.shtml Onbrez® Breezhaler® from Novartis provides greater clinical benefits than tiotropium in new study of COPD patients 2010-11-03T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1458359.shtml Novartis delivers excellent performance in third quarter: recently launched products generate 20%* of sales; Gilenya approved; Alcon consolidated 2010-10-21T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1453762.shtml Novartis obtains CHMP positive opinion for its investigational pre-pandemic influenza vaccine Aflunov® to help protect against (H5N1) avian influenza 2010-09-24T17:38:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1446813.shtml Novartis receives EU approval recommendation for TOBI® Podhaler®, a fast and simple therapy that helps reduce treatment burden for cystic fibrosis patients 2010-09-24T15:16:39 CET http://www.novartis.com/newsroom/media-releases/en/2010/1446760.shtml Novartis study shows Onbrez® Breezhaler® is superior to salmeterol in reducing breathlessness for patients with COPD 2010-09-19T14:40:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1445166.shtml Novartis delivers strong financial performance in second quarter, underpinned by increased momentum in innovation 2010-07-15T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1431809.shtml Novartis erzielt im dritten Quartal eine starke finanzielle Performance sowie Fortschritte in der Pipeline 2011-10-25T08:30:00 CET http://www.novartis.com/newsroom/media-releases/de/2011/1557502.shtml Novartis startet kraftvoll in das Jahr 2011 2011-04-19T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2011/1507512.shtml Novartis réalise, au troisième trimestre, une excellente performance financière et d'importants progrès dans son pipeline 2011-10-25T08:30:00 CET http://www.novartis.com/newsroom/media-releases/fr/2011/1557501.shtml